Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance

Summary AL amyloidosis (AL) and monoclonal gammopathy of renal significance (MGRS) are both paraprotein-associated diseases. Both entities based on a paraprotein produced by clonal plasma-cell population like in undetermined (MGUS) or B-cell low grade lymphoma. Per definition MGUS low-grade lymphoma do not require treatment. But rare cases the M‑gradient acts as “toxic” protein inducing severe multimodal organ damage MGRS. Urgent treatment is indicated MGRS to avoid irreparable loss function death. No currently approved Europe for On January 15, 2021 US Food Drug Administration anti-CD38 antibody AL. To minimize serum concentration, clone directed therapy multiple myeloma B‑cell malignancies regimens can be applied. In AL, an additional option under investigation. These special drugs against typical amyloid-fibrils responsible deposition formation. An important consideration this field diseases transplantation particular kidney All these modalities addressed article.